Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroprotective therapies in stroke

J A Zivin1

  • 1Department of Neurosciences, University of California, San Diego, USA.

Drugs
|January 1, 1997
PubMed
Summary

Current stroke treatments like alteplase (rt-PA) are time-sensitive. While many neuroprotective drugs show promise in animal models, clinical translation for acute stroke remains challenging due to side effects and unproven mechanisms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NeuroThera® Efficacy and Safety Trial-3 (NEST-3): a double-blind, randomized, sham-controlled, parallel group, multicenter, pivotal study to assess the safety and efficacy of transcranial laser therapy with the NeuroThera® Laser System for the treatment of acute ischemic stroke within 24 h of stroke onset.

International journal of stroke : official journal of the International Stroke Society·2012
Same author

The STRokE DOC trial technique: 'video clip, drip, and/or ship'.

International journal of stroke : official journal of the International Stroke Society·2008
Same author

Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.

Neurology·2007
Same author

Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes.

Neuroscience·2007
Same author

Editorial commentary.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

Combination treatment for acute ischemic stroke: A ray of Hope?

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007

Area of Science:

  • Neurology
  • Pharmacology
  • Emergency Medicine

Background:

  • Neuroprotective drugs demonstrate efficacy in reducing neurological damage in animal stroke models.
  • Current acute stroke treatment relies on thrombolysis with alteplase (recombinant tissue-type plasminogen activator; rt-PA), which requires rapid administration.
  • No neuroprotective agents are widely accepted for acute stroke patient treatment.

Purpose of the Study:

  • To review the current status and future directions of neuroprotective drug development for acute stroke.
  • To discuss the challenges and potential of combining neuroprotective strategies with thrombolytic therapy.

Main Methods:

  • Review of existing literature on neuroprotective agents and clinical trials in stroke.
  • Analysis of the efficacy and limitations of glutamate antagonists.
  • Discussion of emerging neuroprotective drug classes and combination therapies.

Main Results:

  • Glutamate antagonists have shown limited clinical success due to dose-limiting phencyclidine-like adverse events.
  • Several other classes of neuroprotectives are under investigation, but their mechanisms are not fully elucidated.
  • Alteplase efficacy confirms the feasibility of acute stroke interventions.

Conclusions:

  • Acute stroke treatment requires rapid intervention, as demonstrated by alteplase therapy.
  • Future clinical trials are likely to explore combinations of novel neuroprotectives with thrombolytics.
  • Further research is needed to overcome the challenges in developing effective neuroprotective drugs for human stroke treatment.

Related Experiment Videos